

LIST OF PUBLICATIONS

A. Original Research Articles (peer reviewed & Pubmed – indexed)

1. Czepiel M, Diviani D, Jaźwa-Kusior A, Tkacz K, Rolski F, Smolenski RT, Siedlar M, **Eriksson U**, Kania G, Blyszczuk P. Angiotensin II receptor 1 controls profibrotic Wnt/ β -catenin signalling in experimental autoimmune myocarditis. **Cardiovasc Res** 2021; cvab039. doi: 10.1093/cvr/cvab039. *Online ahead of print* (IF 6.5)
2. Kovacs B, Reek S, Sticherling C, Schaer B, Linka A, Ammann P, Brenner R, Krasniqi N, Müller AS, Dzemali O, Kobza R, Grebmer C, Haegeli L, Berg J, Mayer K, Schläpfer J, Domenichini G, Reichlin T, Roten L, Burri H, **Eriksson U**, Saguner AM, Steffel J, Duru F, Swiss Wcd Registry. Use of the wearable cardioverter-defibrillator - the Swiss experience. **Swiss Med Wkly** 2020; 150: w20343. doi: 10.4414/smw.2020.20343 (IF 1.8)
3. Vdovenko D, Bachmann M, Wijnen WJ, Hottiger MO, **Eriksson U**, Valaperti A. The adaptor protein c-Cbl-associated protein (CAP) limits pro-inflammatory cytokine expression by inhibiting the NF- κ B pathway. **Int Immunopharmacol** 2020; 87:106822. doi: 10.1016/j.intimp.2020.106822. *Epub 2020 Jul 29* (IF 3.4)
4. Tkacz K, Rolski F, Czepiel M, Działo E, Siedlar M, **Eriksson U**, Kania G, Blyszczuk P. Haploinsufficient Rock1 \pm and Rock2 \pm mice are not protected from cardiac inflammation and postinflammatory fibrosis in Experimental Autoimmune Myocarditis. **Cells** 2020; 9(3):700. doi: 10.3390/cells9030700 (IF 4.3)
5. Arsiwala T, Pahla J, van Tits LJ, Bisceglie L, Gaul DS, Costantino S, Miranda MX, Nussbaum K, Stivala S, Blyszczuk P, Weber J, Tailleux A, Stein S, Paneni F, Beer JH, Greter M, Becher B, Mostoslavsky R, **Eriksson U**, Staels B, Auwerx J, Hottiger MO, Lüscher TF, Matter CM. Sirt6 deletion in bone marrow-derived cells increases atherosclerosis - Central role of macrophage scavenger receptor 1. **J Mol Cell Cardiol** 2020; 139:24-32. doi: 10.1016/j.yjmcc.2020.01.002 (IF 4.1)
6. Zarak-Crnkovic M, Kania G, Jaźwa-Kusior A, Czepiel M, Wijnen WJ, Czyż J, Müller-Edenborn B, Vdovenko D, Lindner D, Gil-Cruz C, Bachmann M, Westermann D, Ludewig B, Distler O, Lüscher TF, Klingel K, **Eriksson U**, Blyszczuk P. Heart non-specific effector CD4 $^{+}$ T cells protect from postinflammatory fibrosis and cardiac dysfunction in experimental autoimmune myocarditis. **Basic Res Cardiol** 2019; 115(1): 6. doi: 10.1007/s00395-019-0766-6 (IF 5.7)
7. Akhmedov A, Montecucco F, Costantino S, Vdovenko D, Schaub Clerigué A, Gaul DS, Burger F, Roth A, Carbone F, Liberale L, Amrollahi-Sharifabadi M, Vellone VG, **Eriksson U**, Matter CM, Crowe LA, Vallée JP, Paneni F, Vanhoutte PM, Camici GG, Mach F, Lüscher TF. Cardiomyocyte-specific JunD overexpression increases infarct size following ischemia/reperfusion cardiac injury by downregulating Sirt3. **Thromb Haemost** 2020; 120(1):168-180. doi: 10.1055/s-0039-3400299 (IF 4.7)
8. Gil-Cruz C, Perez-Shibayama C, De Martin A, Ronchi F, van der Borgh K, Niederer R, Onder L, Lütge M, Novkovic M, Nindl V, Ramos G, Arnoldini M, Slack EMC, Boivin-Jahns V, Jahns R, Wyss M, Mooser C, Lambrecht BN, Maeder MT, Rickli H, Flatz L, **Eriksson U**, Geuking MB, McCoy KD, Ludewig B. Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. **Science** 2019; 366(6467): 881-886 (IF 37.2)
9. Kovacs B, Reek S, Saguner AM, Krasniqi N, **Eriksson U**, Duru F. Outcomes during and after the use of the wearable cardioverter-defibrillator in a tertiary-care and a regional hospital in

Switzerland. **Swiss Med Wkly** 2019; 149: w20136. doi: 10.4414/smw.2019.20136. eCollection 2019 (IF 1.8)

10. Liberale L, Gaul DS, Akhmedov A, Bonetti NR, Nageswaran V, Costantino S, Pahla J, Weber J, Fehr V, Vdovenko D, Semerano A, Giacalone G, Kullak-Ublick GA, Sessa M, **Eriksson U**, Paneni F, Ruschitzka F, Montecucco F, Beer JH, Lüscher TF, Matter CM, Camici GG. Endothelial SIRT6 blunts stroke size and neurological deficit by preserving blood-brain barrier integrity: a translational study. **Eur Heart J** 2020; 41(16):1575-1587. doi: 10.1093/eurheartj/ehz712 (IF 23.4)
11. Weckbach LT, Grabmaier U, Uhl A, Gess S, Boehm F, Zehrer A, Pick R, Salvermoser M, Czermak T, Pircher J, Sorrelle N, Migliorini M, Strickland DK, Klingel K, Brinkmann V, Abu Abed U, **Eriksson U**, Massberg S, Brunner S, Walzog B. Midkine drives cardiac inflammation by promoting neutrophil trafficking and NETosis in myocarditis. **J Exp Med** 2019; 216(2): 350-368 doi: 10.1084/jem.2018102 (IF 12)
12. Kovacs B, Reek S, Krasniqi N, **Eriksson U**, Duru F. Extended use of the Wearable Cardioverter-Defibrillator: which patients are most likely to benefit? **Cardiol Res Pract** 2018; 7373610. doi: 10.1155/2018/7373610. eCollection 2018 (IF 1.1)
13. Gaul DS, Weber J, Van Tits LJ, Sluka S, Pasterk L, Reiner MF, Calatayud N, Lohmann C, Kligenberg R, Pahla J, Vdovenko D, Tanner FC, Camici GG, **Eriksson U**, Auwerx J, Mach F, Windecker S, Rodondi N, L Uuml Scher TF, Winnik S, Matter CM. Loss of Sirt3 accelerates arterial thrombosis by increasing formation of neutrophil extracellular traps and plasma tissue factor activity. **Cardiovasc Res** 2018; 114(8):1178-1188 (IF 6.3)
14. Hofer D, Steffel J, Hürlimann D, Haegeli L, Lüscher TF, Duru F, **Eriksson U**, Krasniqi N. Long-term incidence of inappropriate shocks in patients with implantable cardioverter defibrillators in clinical practice-an underestimated complication? **J Interv Card Electrophysiol** 2017; 50(3): 219-226 (IF 1.5)
15. Blyszczuk P, Müller-Edenborn B, Valenta T, Osto E, Stellato M, Behnke S, Glatz K, Basler K, Lüscher TF, Distler O, **Eriksson U**, Kania G. Transforming growth factor- β -dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis. **Eur Heart J** 2017; 38(18):1413-1425 (IF 23.4)
16. Winnik S, Gaul DS, Siciliani G, Lohmann C, Pasterk L, Calatayud N, Weber J, **Eriksson U**, Auwerx J, van Tits LJ, Lüscher TF, Matter CM. Mild endothelial dysfunction in Sirt3 knockout mice fed a high-cholesterol diet: protective role of a novel C/EBP- β -dependent feedback regulation of SOD2. **Basic Res Cardiol** 2016; 111(3):33 (IF 5.7)
17. Müller-Edenborn B, Kania G, Osto E, Jakob P, Krasniqi N, Beck-Schimmer B, Blyszczuk P, **Eriksson U**. Lidocaine enhances contractile function of ischemic myocardial regions in a mouse model of sustained myocardial ischemia. **PLoS One** 2016; 11(5):e0154699 (IF 2.8)
18. Thelemann C, Haller S, Blyszczuk P, Kania G, Rosa M, **Eriksson U**, Rotman S, Reith W, Acha-Orbea H. Absence of nonhematopoietic MHC class II expression protects mice from experimental autoimmune myocarditis. **Eur J Immunol** 2016; 46(3):656-664 (IF 4.2)
19. Männ L, Kochupurakkal N, Martin C, Verjans E, Klingberg A, Sody S, Kraus A, Dalimot J, Bergmüller E, Jung S, Voortman S, Winterhager E, Brandau S, Garbi N, Kurrer M, **Eriksson U**, Gunzer M, Hasenberg M. CD11c.DTR mice develop a fatal fulminant myocarditis after local or systemic treatment with diphtheria toxin. **Eur J Immunol** 2016; 46(8):2028-2042 (IF 4.2)
20. Grabmaier U, Kania G, Kreiner J, Grabmeier J, Uhl A, Huber BC, Lackermair K, Herbach N, Todica A, **Eriksson U**, Weckbach LT, Brunner S. Soluble Vascular Cell Adhesion Molecule-1 (VCAM-1) as a Biomarker in the Mouse Model of Experimental Autoimmune Myocarditis (EAM). **PLoS One** 2016; 11(8):e0158299 (IF 2.8)

21. Hoetzenecker K, Zimmermann M, Hoetzenecker W, Schweiger T, Kollmann D, Mildner M, Hegedus B, Mitterbauer A, Birner P, Blyszczuk P, **Eriksson U**, Ankersmit HJ. Mononuclear cell secretome protects from experimental autoimmune myocarditis. *Eur Heart J* 2015; 36:676-685 (IF 23.4)
22. Valaperti A, Nishii M, Liu Y, Yang H, Naito K, Liu PP, **Eriksson U**. The adaptor protein c-Cbl-associated protein (CAP) protects from acute CVB3-mediated myocarditis through stabilization of type I interferon production and reduced cytotoxicity. *Basic Res Cardiol* 2014; 109:411 (IF 5.7)
23. Schurter D, Rauber-Lüthy C, Jahns M, Haberkern M, Kupferschmidt H, Exadaktylos A, **Eriksson U**, Ceschi A. Factors that trigger emergency physicians to contact a poison centre: findings from a Swiss study. *Postgrad Med J* 2014; 90:139-143. (IF 2)
24. Valaperti A, Nishii M, Germano D, Liu PP, **Eriksson U**. Vaccination with Flt3L-induced CD8a+ dendritic cells prevents CD4+ T helper cell-mediated experimental autoimmune myocarditis. *Vaccine* 2013; 31:4802-4811. (IF 3.2)
25. Valaperti A, Nishii M, Liu Y, Naito K, Chan M, Zhang L, Skurk C, Schultheiss HP, **Eriksson U**, Liu PP. Innate Immune Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Exacerbates Viral Myocarditis by Reducing CCR5+CD11b+ Monocytes Migration and Impairing Interferon Production. *Circulation* 2013; 128:1542-1554. (IF 18.8)
26. Jenke A, Wilk S, Poller W, **Eriksson U**, Valaperti A, Rauch B, Stroux A, Liu PP, Schultheiss HP, Scheibenbogen C, Skurk C. Adiponectin protects against Toll-like receptor 4 mediated cardiac inflammation and injury. *Cardiovasc Res* 2013; 99:422-431. (IF 6.3)
27. Kania G, Siegert S, Behnke S, Prados-Rosales R, Casadevall A, Lüscher TF, Luther SA, Kopf M, **Eriksson U***, Blyszczuk P*. Innate signalling promotes formation of regulatory nitric oxide-producing dendritic cells limiting T cell expansion in experimental autoimmune myocarditis. *Circulation* 2013; 127:2285 – 2295. **shared last authorship* (IF 18.8)
28. Speer T, Rohrer LP, Blyszczuk P, Shroff R, Kuschnerus K, Kränkel N, Kania G, Zewinger S, Martin T, Akhmedov A, Shi Y, Perisa D, Winnik S, Müller MF, Wernicke G, Jung A, Gutteck U, Deanfield J, **Eriksson U**, von Eckardstein A, Lüscher TF, Fliser D, Bahlmann F, Landmesser U. Abnormal High-Density Lipoprotein Induces Endothelial Dysfunction via Activation of Toll-Like Receptor-2. *Immunity* 2013; 38:754 – 768. (IF 19.7)
29. Heeswijk RB, De Blois J, Kania G, Gonzales C, Blyszczuk P, Stuber M, **Eriksson U**, Schwitler J. Selective in-vivo visualization of immune-cell infiltration in a mouse model of autoimmune myocarditis by fluorine-19 cardiac magnetic resonance. *Circ Cardiovasc Imaging* 2013; 6(2):277-284. (IF 6.2)
30. Blyszczuk P, Behnke S, Lüscher TF, **Eriksson U**, Kania G. GM-CSF promotes inflammatory dendritic cell formation but does not contribute to disease progression in experimental autoimmune myocarditis. *Biochim Biophys Acta* 2013; 1833:934-944. (IF 5.3)
31. Blyszczuk P, Berthonneche C, Behnke S, Glöckler M, Moch H, Pedrazzini T, Lüscher TF, **Eriksson U***, Kania G*. Nitric oxide synthase 2 is required for conversion of fibrogenic CD133+ progenitors into F4/80+ macrophages in experimental autoimmune myocarditis. *Cardiovasc Res* 2013; 97:219-229. **shared last authorship* (IF 6.3)
32. Fox J, Fiechter R, Gerstl P, Url A, Wagner H, Lüscher TF, **Eriksson U**, Wyss CA. Mechanical versus manual chest compression CPR under ground ambulance transport conditions. *Acute Card Care* 2013; 15(1):1-6. (IF 1.1)

33. Blyszczuk P, Germano D, Stein S, Moch H, Matter CM, Beck-Schimmer B, Lüscher TF, **Eriksson U**, Kania G. Profibrotic potential of Prominin-1⁺ epithelial progenitor cells in pulmonary fibrosis. *Respir Res* 2011; 12:126-130. (IF 3.8)
34. Bobbert P, Scheibenbogen C, Jenke A, Kania G, Wilk S, Krohn S, Stehr J, Kuehl U, Rauch U, **Eriksson U**, Schultheiss HP, Poller W, Skurk C. Adiponectin expression in patients with inflammatory cardiomyopathy indicates favourable outcome and inflammation control. *Eur Heart J* 2011; 32(9):1134-1147. (IF 23.4)
35. Hunziker S, Hügle T, Schuchardt K, Groeschl I, Schuetz P, Mueller B, Dick W, **Eriksson U**, Trampuz A. The Value of Procalcitonin for Differentiation of Infectious from Non-Infectious Causes of Fever after Orthopedic Surgery. *J Bone Joint Surg Am* 2010; 92:917-921. (IF 4.8)
36. Rother M, Krohn S, Kania G, Vanhoutte D, Eisenreich A, Wang X, Westermann D, Savvatis K, Dannemann N, Skurk C, Hilfiker-Kleiner D, Cathomen T, Fechner H, Rauch U, Schultheiss HP, Heymans S, **Eriksson U**, Scheibenbogen C, Poller W. Matricellular Signaling Molecule CCN1 Attenuates Experimental Autoimmune Myocarditis by Acting as a Novel Immune Cell Migration Modulator. *Circulation* 2010; 122:2688-2698. (IF 18.8)
37. Blyszczuk P, Kania G, Dieterle T, Marty RR, Valaperti A, Bertonneche C, Pedrazzini T, Berger CT, Dirnhofer S, Matter CM, Penninger JM, Lüscher TF, **Eriksson U**. MyD88/IL-1 signaling controls cardiac fibrosis and heart failure progression in inflammatory dilated cardiomyopathy. *Circ Res* 2009; 105:912-920. (IF 14)
38. Kania G, Blyszczuk P, Stein MS, Valaperti A, Germano D, Dirnhofer S, Hunziker L, Matter CM, **Eriksson U**. Heart-infiltrating prominin-1⁺/CD133⁺ progenitor cells represent the cellular source of TGF- β -mediated cardiac fibrosis in experimental autoimmune myocarditis. *Circ Res* 2009; 105:462-470. (IF 14)
39. Germano D, Blyszczuk P, Valaperti A, Kania G, Dirnhofer S, Landmesser U, Lüscher TF, Hunziker L, Zulewski H, **Eriksson U**. Prominin-1/CD133⁺ lung epithelial progenitor cells protect from bleomycin-induced pulmonary fibrosis. *Am J Resp Crit Care* 2009; 179:939-949. (IF 15.2)
40. Mauermann N, Burian J, Dirnhofer S, Bingisser RM, Tamm M, **Eriksson U**^{*}, Hunziker L. Interferon regulates idiopathic pneumonia syndrome, a Th17 CD4 T cell mediated GvH disease. *Am J Resp Crit Care* 2008; 178:379-388. **shared last authorship* (IF 15.2)
41. Kania G, Blyszczuk P, Valaperti A, Dieterle T, Leimenstoll B, Dirnhofer S, Zulewski H, **Eriksson U**. Prominin-1⁺/CD133⁺ bone marrow derived heart resident cells suppress experimental autoimmune myocarditis. *Cardiovasc Res* 2008; 80:236-245. (IF 6.3)
42. Valaperti A, Marty RR, Kania G, Germano D, Mauermann N, Dirnhofer S, Leimenstoll B, Blyszczuk P, Hunziker L, **Eriksson U**. CD11b⁺ monocytes abrogate Th17 CD4⁺ T cell mediated experimental autoimmune myocarditis. *J Immunol* 2008; 180:2686-2695. (IF 4.5)
43. Munk VC, de Miguel LS, Petrimpol M, Butz N, Banfi A, **Eriksson U**, Hein L, Humar R, Battegay EJ. Angiotensin II induces angiogenesis in the hypoxic adult mouse heart in vitro through an AT2-B2 receptor pathway. *Hypertension* 2007; 49:1178-1185. (IF 5.4)
44. Rangachari M, Mauermann N, Marty RR, Dirnhofer S, Kurrer MO, Komnenovic V, Penninger JM, **Eriksson U**. T-bet is a negative regulator of autoimmune heart disease. *J Exp Med* 2006; 203:2009-2019. (IF 12)
45. Marty RR, Dirnhofer S, Mauermann N, Schweikert S, Akira S, Hunziker L, Penninger JM, **Eriksson U**. MyD88 signaling controls autoimmune myocarditis induction. *Circulation* 2006; 113:258-265. (IF 18.8)

46. Abel B, Kurrer MO, Shamshiev J, Marty RR, **Eriksson U**, Gunthert U, Kopf M. The osteopontin – CD44 pathway is superfluous for the development of autoimmune myocarditis. **Eur J Immunol** 2006; 36:494-499. (IF 4.2)
47. Christ A, Arranto CA, Schindler C, Klima T, Hunziker PR, Siegemund M, Marsch SC, **Eriksson U**, Mueller C. Incidence, risk factors, and outcome of aspiration pneumonitis in ICU overdose patients. **Intensive Care Med** 2006; 32(9):1423-1427. (IF 10.1)
48. **Eriksson U**, Egermann U, Bihl MP, Gambazzi F, Tamm M, Holt PG, Bingisser RM. Human bronchial epithelium controls TH2 responses by TH1 induced nitric oxide-mediated STAT5 dephosphorylation: implications for the pathogenesis of asthma. **J Immunol** 2005; 175:2715-2720. (IF 4.5)
49. Ricci R, **Eriksson U**, Oudit GY, Eferl R, Akhmedov A, Sumara I, Sumara G, Kassiri Z, David JP, Bakiri L, Sasse B, Idarraga MH, Rath M, Kurz D, Theussl HC, Perriard J, Backx P, Penninger JM, Wagner EF. Distinct function of junD in cardiac hypertrophy and heart failure. **Gene Dev** 2005; 19:208-213. (IF 9.4)
50. Ricci R, Sumara G, Sumara I, Rozenberg I, Kurrer MO, Akhmedov A, Hersberger M, **Eriksson U**, Eberli FR, Becher B, Boren J, Chen M, Cybulsky MI, Moore KJ, Freeman MW, Wagner EF, Matter CM, Luscher TF. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. **Science** 2004; 306:1558-1561. (IF 37.2)
51. **Eriksson U**, Ricci R, Hunziker L, Kurrer MO, Oudit GY, Watts TH, Sonderegger I, Bachmaier K, Kopf M, Penninger JM. Dendritic cell-induced heart failure requires essential cooperation between adaptive and innate immunity. **Nat Med** 2003; 9:1484-1489. (IF 32.6)
52. **Eriksson U**, Kurrer MO, Sonderegger I, Iezzi G, Tafuri A, Hunziker L, Suzuki S, Bachmaier K, Bingisser RM, Penninger JM, Kopf M. Activation of dendritic cells through the IL-1 receptor 1 is essential for the induction of autoimmune myocarditis. **J Exp Med** 2003; 197(3):323-331. (IF 12)
53. Arranto CR, Mueller C, Hunziker PR, Marsch SC, **Eriksson U**. Adverse cardiac events in ICU patients with presumed antidepressant intoxication: a prospective observational study. **Swiss Med Wkly** 2003; 133:479-483. (IF 1.8)
54. Oudit GY, Crackower MA, **Eriksson U**, Sarao R, Kozieradzki I, Sasaki T, Irie-Sasaki J, Gidrewicz D, Rybin VO, Wada T, Steinberg SF, Backx PH, Penninger JM. Phosphoinositide 3 Kinase γ -deficient mice are protected from isoproterenol-induced heart failure. **Circulation** 2003; 108:2147-2152. (IF 18.8)
55. **Eriksson U**, Kurrer MO, Schmitz N, Fontana A, Marsch SC, Eugster HP, Kopf M. IL-6 deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of Complement C3. **Circulation** 2003; 107:320-325. (IF 18.8)
56. Suzuki N, Suzuki S, **Eriksson U**, Hara H, Mirtosis C, Chen NJ, Wada T, Bouchard D, Hwang I, Takeda K, Fujiata T, Der S, Penninger JM, Akira S, Saito T, Yeh WC. IRAK-4 is required for LPS-induced activation of antigen-presenting cells. **J Immunol** 2003; 171:6065-6071. (IF 4.5)
57. Mak TW, Shahinian A, Yoshinaga S, Wakeham, Boucher L, Gajewska B, Pintilie M, Gronski M, **Eriksson U**, Odermatt B, Ho A, Bouchard D, Whorsky JS, Jordana M, Pawson T, Ohashi P, Blatt F, Tafuri A. Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cell-dependent B cell responses. **Nat Immunol** 2003; 4:765-772. (IF 21.8)
58. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, **Eriksson U**, Marsch SC, Roskamm H. Prevention of contrast media-associated nephropathy: randomized comparison of

- two hydration regimens in 1620 patients undergoing coronary angioplasty **Arch Intern Med** 2002; 162:329-336. (IF 19.9)
59. **Eriksson U**, Kurrer MO, Sebald W, Brombacher F, Kopf M. Dual role of the IL-12/IFN- γ axis in the development of myocarditis: induction by IL-12 and protection by IFN- γ . **J Immunol** 2001; 167:5464-5469. (IF 4.5)
60. **Eriksson U**, Kurrer MO, Bingisser RM, Eugster HP, Saremaslani P, Follath F, Marsch S, Widmer U. Lethal autoimmune myocarditis in Interferon- γ receptor deficient mice: enhanced disease severity by impaired inducible nitric oxide induction. **Circulation** 2001; 96:585-591. (IF 18.8)
61. **Eriksson U**, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial **Brit Med J** 2001; 322:579-585. (IF 23.3)
62. **Eriksson U**, Duc G, Froesch ER, Zapf J. Insulin-like growth factors (IGF) I and II and IGF binding proteins (IGFBPs) in human colostrum/transitory milk during the first week postpartum: comparison with neonatal and maternal serum. **Biochem Biophys Res Commun** 1993; 196:267-273. (IF 2.5)

B. Position Papers (peer reviewed & Pubmed - indexed)

63. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, **Eriksson U**, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. **Eur Heart J** 2021; ehab072. doi: 10.1093/eurheartj/ehab072. *Online ahead of print.*
64. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, **Eriksson U**, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. **Eur J Heart Fail** 2021; doi: 10.1002/ejhf.2140. *Online ahead of print.*
65. Caforio ALP, Adler Y, Agostini C, Allanore Y, Anastasakis A, Arad M, Böhm M, Charron P, Elliott PM, **Eriksson U**, Felix SB, Garcia-Pavia P, Hachulla E, Heymans S, Imazio M, Klingel K, Marcolongo R, Matucci Cerinic M, Pantazis A, Plein S, Poli V, Rigopoulos A, Seferovic P, Shoenfeld Y, Zamorano JL, Linhart A. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. **Eur Heart J** 2017; 38(35):2649-2662 (IF 23.4)

C. Case Reports (peer reviewed & Pubmed - indexed)

66. Latifi Y, Gugelmann R, Rigger J, Preiswerk B, **Eriksson U**, Eberli FR, Bernheim AM. Effusive-Constrictive Pericarditis due to Immune Reconstitution Inflammatory Syndrome following Tuberculous Pericarditis. **CASE (Phila)** 2020; 27;5(1):67-72. doi: 10.1016/j.case.2020.10.012. eCollection 2021
67. Yakupoglu HY, Baran T, Baumann F, **Eriksson U**, Krasniqi N. Recurrent syncope after a finger injury and induced monomorphic ventricular tachycardia: Really Brugada syndrome? **J Electrocardiol** 2020; 63:120-123.

68. Benz DC, Fuchs TA, Tanner FC, **Eriksson U**, Yakupoglu HY. Multimodality imaging of a right ventricular mass. *Eur Heart J Cardiovasc Imaging* 2019; 20(10):1184. doi: 10.1093/ehjci/jez087.
69. Winnik S, Hitz A, Wyden S, Peter U, **Eriksson U**, Stieger R. [Exacerbation of chronic lower back pain with an unexpected twist]. *Praxis* 2013; 102(12):745-750.
70. Benz DC, Krasniqi N, Wagnet U, Sieger R, Tanner FC, **Eriksson U**. Isolated persistent left superior vena cava draining in to the left atrium of an otherwise normal heart. *Eur Heart J* 2013; 34:1505.
71. Wölnerhanssen BK, Langer I, **Eriksson U**, Schneider M. Sudden death after open gastric bypass surgery. *Langenbecks Arch Surg* 2009; 394:573-577.
72. Burri E, Decker M, **Eriksson U**, Buser P, Hunziker L. 28-year old patient with successfully treated dilated cardiomyopathy *Internist* 2008; 49(3):349-352.
73. Schuetz P, **Eriksson U**, Christ-Crain M, Zulewski H, Muller B. [Amiodarone-induced thyrotoxicosis: a diagnostic and therapeutic challenge]. *Praxis* 2005; 94(36):1397-401.
74. Ramazzina C, Bremerich J, Linka A, **Eriksson U**. Asymptomatic myocarditis after infection of the upper respiratory tract. *Dtsch Med Wochenschr* 2005; 130:1311-1313.
75. Tietz A, Heim MH, **Eriksson U**, Marsch S, Terracciano L, Krahenbuhl S. Fulminant liver failure associated with clarithromycin. *Ann Pharmacother* 2003; 37(1):57-60.
76. Rudiger JJ, **Eriksson U**, Schiller P, Leuppi JD. Henoch-Schoenlein syndrome in a 80-year-old patient. *Dtsch Med Wochenschr* 2002; 127(25/26):1382-1384.
77. Buser A, Khanlari B, Faeh F, Osswald S, **Eriksson U**. Rezidivierende Synkopen und rhythmogener Schock. *Schweiz Med Forum* 2002; 37:874-876.
78. **Eriksson U**, Atar D, Krähenmann F, Maggiorini M, Kiowski W, Follath F. Profound ECG abnormalities during emergency cesarean section in a patient with pre-eclampsia. *Scand Cardiovasc J* 1999; 33(3):183-186.
79. **Eriksson U**, Opravil M, Amann FW, Schaffner A. Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients? *AIDS* 1998;12(15):2079-2080.
80. **Eriksson U**, Frick H. Neurosyphilis 12 years after treatment of primary infection in a meanwhile HIV infected patient. *Schweiz Med Wochenschr* 1997; 27(22):940-944.

D. Review Articles (peer reviewed and Pubmed-indexed)

81. Odening KE, Dies S, Dilling-Boer D, Didenko M, **Eriksson U**, Nedios S, Ng FS, Roca Luque I, Sanchez Borque P, Vernoooy K, Wijnmaalen AP, Yorgun H. Mechanisms of sex differences in atrial fibrillation: role of hormones and differences in electrophysiology, structure, function, and remodelling. *Europace* 2019; 21(3): 366 – 376 doi: 10.1093/europace/euy215 (Epub ahead of print) (IF 5.2)
82. Vdovenko D, **Eriksson U**. Regulatory role of CD4+ T cells in Myocarditis. *J Immunol Res* 2018; 4396351. Doi: 1155/2018/4396351. eCollection 2018 (IF 3.3)
83. Heymans S, **Eriksson U**, Lehtonen J, Cooper LT. The Quest for New Approaches in Myocarditis. *J Am Coll Cardiol* 2016; 68(21):2348-2364 (IF 16.8)

84. Kania G, Blyszczuk P, Müller-Edenborn B, **Eriksson U**. Novel therapeutic options in inflammatory cardiomyopathy. *Swiss Med Wkly* 2013; 143:w13841. doi: 10.4414/smw.2013.13841. (IF 1.8)
85. Müller-Edenborn B, **Eriksson U**. Herzinsuffizienz – Update. *Schweiz Rundschau Med Prax* 2013; 102:1053-1060.
86. Cakic S, **Eriksson U**. Sports and inflammatory heart disease. *Schweiz Zeitschr "Sportmedizin & Sporttraumatologie"* 2011; 59(2): 87-89.
87. Kania G, Blyszczuk P, **Eriksson U**. Mechanisms of cardiac fibrosis in inflammatory heart disease. *Trends Cardiovasc Med* 2009; 19:247-252. (IF 4.6)
88. Blyszczuk P, Valaperti A, **Eriksson U**. Future therapeutic strategies in inflammatory cardiomyopathy: insights from the experimental autoimmune myocarditis model. *Cardiovasc Hematol Disord Drug Targets* 2008; 8:297-305.
89. Marty RR, **Eriksson U**. Dendritic cell-induced autoimmune heart failure. *Int J Cardiol* 2006;112(1):34-39. (IF 4)
90. Gasser S, **Eriksson U**. Der septische Schock: Diagnostik und Management. *Schweiz Rundschau Med Prax* 2005; 94:765-769.
91. Burian J, Buser P, **Eriksson U**. Myocarditis: the immunologist's view on pathogenesis and treatment. *Swiss Med Wkly* 2005; 135:359-364. (IF 1.8)
92. **Eriksson U**, Penninger JM. Medicine in focus: autoimmune heart failure - new understanding of pathogenesis. *Int J Biochem Cell Biol* 2005; 37:27-32. (IF 4.2)
93. Danilczyk U, **Eriksson U**, Oudit GY, Penninger JM. Physiological roles of angiotensin converting enzyme 2. *Cell Mol Life Sci* 2004; 61:2714-2719. (IF 6.7)
94. Danilczyk U, **Eriksson U**, Crackower MA, Penninger JM. A story of two ACEs. *J Mol Med* 2003; 81:227-234. (IF 4.9)
95. **Eriksson U**, Danilcyk U, Penninger JM. It's only the beginning: Novel functions for angiotensin converting–enzymes. *Curr Biol* 2002; 12:R745-R752. (IF 8.8)
96. Kurrer MO, Kopf M, Penninger JM, **Eriksson U**. Cytokines that regulate autoimmune myocarditis – a minireview. *Swiss Med Wkly* 2002; 132:408-413. (IF 1.8)

E. Bookchapters

97. **Eriksson U**. "Autoimmune heart disease animal models" in Encyclopedia of Medical Immunology 2012. Edited by N. Rose. Springer Basel.
98. **Eriksson U**. "The role of IL-17 in experimental autoimmune myocarditis" in "Th17 cells: role in inflammation and autoimmune disease". Progress in Inflammatory Research, 2012, Part 3, 115-126. Springer Basel.
99. **Eriksson U**. Chapter 7.2.; "Myokarditis" in Steffel & Lüscher: Herz-Kreislauf. Springer Lehrbuch 2010; New edition 2014.
100. Berger C & **Eriksson U**. „Autoimmune murine myocarditis and immunomodulatory interventions“ in „Inflammatory Cardiomyopathy (DCMi). Progress in Inflammatory Research, 2010, Part 2, 37-49. Springer Basel.

101. Valaperti A & **Eriksson U**. "The role of IL-17 in experimental autoimmune myocarditis" in "Th17 cells: role in inflammation and autoimmune disease". Progress in Inflammatory Research, 2009, Part 3, 115-126. Springer Basel.
102. **Eriksson U**. „Autoimmunity and heart failure“ in „Immune Dysfunction and Immunotherapy in Heart Disease“. Edited by Watson R & Larson DF. Blackwell Publishing, Oxford, UK. November 2007

F. Non Pubmed-indexed publications, and Editorials

103. Rusterholz S, Fiechter R, **Eriksson U**, Ekkehardt A, Wittwer M, Schuerch N, Karrer U, Hofer D. Tularämie – eine seltene Ursache der Pneumonie. **Schweiz Med Forum** 2018; doi: 10.4414/smf.2018.03235
104. Kovacs B, Reek S, Krasniqi N, **Eriksson U**, Duru F. Die tragbare Defibrillatorweste. **Schweiz Med Forum** 2018; doi: 10.4414/smf.2018.03301
105. Schwegler E, Bachmann M, **Eriksson U**, Krasniqi N. **Pericarditis** in a Swiss regional hospital. **Cardiovasc Med**. 2017; 20(12):300-304.
106. **Eriksson U**. Physician, engineer, inventor and entrepreneur: Dr. Johannes Müller has contributed to Berlin's reputation as a hot-spot for Med-Tech companies. **Eur Heart J** 2015; 36:138-139.
107. Krasniqi N & **Eriksson U**. Gene expression profiling: time to file diagnostic uncertainty in inflammatory heart diseases? [Editorial]. **Eur Heart J** 2014; 35:2138-2139.
108. Krasniqi N, Horisberger S, Siegrist PT, Fuchs TA, Saguner A, Scherff F, **Eriksson U**, Corti R, Lüscher TF. Analysis of admission electrocardiographic patterns in survivors and non-survivors of unprotected left main acute coronary syndrome undergoing percutaneous coronary intervention. **J Cardiobiol** 2014; 2:5-10.
109. Müller-Edenborn B, Wagnetz U, Müller JD, **Eriksson U**. Komplikation bei Schrittmachereinlage. **Schweiz Med Forum** 2013; 13:189.
110. Mocetti F, Müller-Edenborn B, Weder W, **Eriksson U**. Dyspnea and impaired ventricular filling due to infiltration of the left atrium with a lung adenocarcinoma. **Cardiovasc Med** 2012; 15(9): 261-262.
111. **Eriksson U**. Tackling inflammatory heart disease: how to get dirty glasses clean with dirty towels. [Editorial]. **Cardiology** 2009; 114:103-104.
112. Schaub N, Ilic M, Gürke L, **Eriksson U**. Bacteroides fragilis assoziierte Aortitis abdominalis. **Schweiz Med Forum** 2008; 8:781-783.
113. **Eriksson U**. Chlamydia and myocarditis: an old bug bugging seriously. [Editorial]. **Crit Care Med** 2007; 35:670-672.
114. Rangachari M, **Eriksson U**, Vollmann E, Penninger JM. A novel model for pathogenesis of autoimmune heart failure: The role of dendritic cells. **Int Congr Ser** 2005; 1285:192–201.
115. **Eriksson U**, Penninger JM, Kopf M. Mechanisms of autoimmune heart disease. **Drug Discovery Today: Disease Mechanisms** 2004; 1(3):283-288 (ONLINE ONLY).
116. **Eriksson U**, Kopf M, Afanasyeva M, Penninger JM. Models of autoimmune heart disease. **Drug Discovery Today: Disease Models** 2004; 1(4):411-416 (ONLINE ONLY).

117. **Eriksson U**, Sahrbacher U, Widmer U. Intestinal focal-nodular hyperplasia in "common variable immunodeficiency". ***Schweiz Med Wochenschr*** 1999; 129(43):1632.
118. Kael GM, Schubiger C, **Eriksson U**. Neuroendocrine carcinoma. ***Schweiz Med Wochenschr*** 1998;128(48):1915.